Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.32 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.32 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | TYMS | P04818 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20445639 | 0.79 | KDM4E (0.46) | MAP2K1CHRM2ADRA2AALDH1A1GAA | |
| SCHEMBL897309 | 0.75 | HTR5A (0.43) | ALDH1A1MEN1KMT2AKDM4ELMNA | |
| SCHEMBL18495510 | 0.75 | PDE7A (0.36) | MAP2K1MEN1KMT2ANPC1MAPK13 | |
| SCHEMBL34461280 | 0.73 | ALOX5 (0.39) | ALDH1A1GAAMEN1KMT2ANPC1 | |
| SCHEMBL22989715 | 0.71 | LIMK1 (0.33) | MAP2K1ALDH1A1GAAMEN1KMT2A | |
| SCHEMBL2061748 | 0.71 | CHRM2 (0.49) | CHRM2ADRA2AALDH1A1NPC1MAPK13 | |
| SCHEMBL29858318 | 0.71 | CHRM2 (0.49) | CHRM2ADRA2AALDH1A1NPC1MAPK13 | |
| SCHEMBL20656717 | 0.68 | MAP2K1 (0.39) | MAP2K1ABHD6CA9 | |
| SCHEMBL18440401 | 0.68 | KDM1A (0.39) | ALDH1A1MEN1KMT2A | |
| SCHEMBL20004157 | 0.66 | MEN1 (0.40) | ALDH1A1GAAMEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834456-B2 | 11,13-modified saxitoxins for the treatment of pain | SITEONE THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834456-B2 | 11,13-modified saxitoxins for the treatment of pain | SITEONE THERAPEUTICS, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-20230055376-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARMACEUTICALS, INC. | 2023-02-23 | — | — | US | disclosed |
| US-20230055376-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARMACEUTICALS, INC. | 2023-02-23 | — | — | US | disclosed |
| EP-3328835-B1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARM INC (US) | 2022-10-12 | — | — | EP | disclosed |
| US-11395824-B2 | 5-HT2C receptor agonists and compositions and methods of use | ARENA PHARMACEUTICALS, INC. (US) | 2022-07-26 | — | — | US | disclosed |
| CN-108137508-B | 5-HT2CReceptor agonists and compositions and methods of use | 艾尼纳制药公司 | 2021-08-27 | — | — | CN | disclosed |
| US-20200383993-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARMACEUTICALS, INC. | 2020-12-10 | — | — | US | disclosed |
| US-20200383993-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARMACEUTICALS, INC. | 2020-12-10 | — | — | US | disclosed |
| US-10624900-B2 | 5-HT2C receptor agonists and compositions and methods of use | ARENA PHARMACEUTICALS, INC. (US) | 2020-04-21 | — | — | US | disclosed |
| US-10624900-B2 | 5-HT2C receptor agonists and compositions and methods of use | ARENA PHARMACEUTICALS, INC. (US) | 2020-04-21 | — | — | US | disclosed |
| US-20200078368-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARMACEUTICALS, INC. | 2020-03-12 | — | — | US | disclosed |
| US-10272094-B2 | 5-HT2C receptor agonists and compositions and methods of use | ARENA PHARMACEUTICALS, INC. (US) | 2019-04-30 | — | — | US | disclosed |
| US-10272094-B2 | 5-HT2C receptor agonists and compositions and methods of use | ARENA PHARMACEUTICALS, INC. (US) | 2019-04-30 | — | — | US | disclosed |
| US-20180214455-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARMACEUTICALS, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20180214455-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARMACEUTICALS, INC. | 2018-08-02 | — | — | US | disclosed |
| US-20180214455-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARMACEUTICALS, INC. | 2018-08-02 | — | — | US | disclosed |
| EP-3328835-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | Arena Pharmaceuticals, Inc. (US) | 2018-06-06 | — | — | EP | disclosed |
| WO-2017023679-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARMACEUTICALS, INC. (US) | 2017-02-09 | — | — | WO | disclosed |
| WO-2017023679-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARMACEUTICALS, INC. (US) | 2017-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10624900-B2 | 5-HT2C receptor agonists and compositions and methods of use | HTR2C, HTR2A, HCRTR2 | MAP2K1 3710/4885CHRM2 130/4885ADRA2A 26/4885 |
| US-20180214455-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | HTR2C, HTR2A, HCRTR2 | MAP2K1 3710/4885CHRM2 130/4885ADRA2A 26/4885 |
| US-11834456-B2 | 11,13-modified saxitoxins for the treatment of pain | SCN11A, SCN10A, CACNA1A | MAP2K1 4729/4885CHRM2 139/4885ADRA2A 178/4885 |
| US-20230055376-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | HTR2C, HTR2A, HCRTR2 | MAP2K1 3710/4885CHRM2 130/4885ADRA2A 26/4885 |
| US-20200078368-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | HTR2C, HTR2A, HCRTR2 | MAP2K1 3710/4885CHRM2 130/4885ADRA2A 26/4885 |
| US-10272094-B2 | 5-HT2C receptor agonists and compositions and methods of use | HTR2C, HTR2A, HCRTR2 | MAP2K1 3710/4885CHRM2 130/4885ADRA2A 26/4885 |
| US-20200383993-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | HTR2C, HTR2A, HCRTR2 | MAP2K1 3710/4885CHRM2 130/4885ADRA2A 26/4885 |
| US-11395824-B2 | 5-HT2C receptor agonists and compositions and methods of use | HTR2C, HTR2A, HCRTR2 | MAP2K1 3710/4885CHRM2 130/4885ADRA2A 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.